Related Experiment Videos
[Clinical study of GM-CSF in patients with aplastic anemia and myelodysplastic syndrome. (CSF39-300 Study Group)]
K Kitamura1, S Asano, H Mizoguchi
1Clinical Laboratory Center, Faculty of Medicine, University of Tokyo.
Insights
Granulocyte-macrophage colony-stimulating factor (GM-CSF) effectively stimulated blood cell production in patients with aplastic anemia and myelodysplastic syndrome (MDS). This treatment showed positive results, with manageable side effects, highlighting GM-CSF
Area of Science:
- Hematology
- Oncology
Background:
- Aplastic anemia and myelodysplastic syndrome (MDS) are serious bone marrow failure disorders.
- Current treatments have limitations, necessitating exploration of novel therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aplastic anemia and MDS.
Main Methods:
- A phase III clinical trial was conducted.
- Patients received GM-CSF via a 3-hour intravenous drip infusion daily for at least 14 days.
- Efficacy was assessed in 25 patients with aplastic anemia and 19 patients with MDS.
Main Results:
- GM-CSF administration led to marked increases in peripheral blood granulocyte counts, including neutrophils and eosinophils, in both patient groups.
- Positive responses to GM-CSF were observed in 19/25 patients with aplastic anemia and 15/19 patients with MDS.
- A dose-related increase in granulocytes was noted in MDS patients, but not in aplastic anemia patients.
- Common adverse effects included transient flu-like symptoms such as fever, fatigue, and anorexia.
Conclusions:
- GM-CSF is a potent stimulator of hematopoiesis in patients suffering from aplastic anemia and MDS.
- The observed hematological improvements suggest GM-CSF's therapeutic potential in these conditions.
Abstract:
We administered granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with aplastic anemia and myelodysplastic syndrome (MDS), as a phase III trial. The GM-CSF was given by 3 hrs intravenous drip infusion daily for at least fourteen days. Twenty-five patients with aplastic anemia and nineteen patients with MDS were evaluable for efficacy. Peripheral blood granulocyte counts, especially neutrophil counts and eosinophil counts, increased markedly by the administration of GM-CSF in each disease. Fifteen patients with MDS and nineteen patients with aplastic anemia responded to the GM-CSF. Dose-related increase of granulocytes were seen in patients with MDS, but no relation was seen in patients with aplastic anemia. Adverse effects were observed in some patients and flu-like syndrome including fever, general fatigue and anorexia were seen most commonly but were transient. Our results showed that GM-CSF is a potent stimulator of hematopoiesis in patients with aplastic anemia and MDS.